TipRanks
Advertisement
Advertisement
TransMedics initiated with an Overweight at Barclays
PremiumThe FlyTransMedics initiated with an Overweight at Barclays
17d ago
Analyst Reiterates Buy on TransMedics, Citing Strong Near-Term Revenue Upside and Multiple Long-Term Growth Catalysts
Premium
Ratings
Analyst Reiterates Buy on TransMedics, Citing Strong Near-Term Revenue Upside and Multiple Long-Term Growth Catalysts
22d ago
TransMedics Group: Buy Rating Reiterated, $106 Price Target Maintained on Strengthened Leadership and Robust 2026 Growth Outlook
Premium
Ratings
TransMedics Group: Buy Rating Reiterated, $106 Price Target Maintained on Strengthened Leadership and Robust 2026 Growth Outlook
1M ago
TransMedics: Expanding Growth Platform, Strong Clinical Catalysts, and Improving Fundamentals Underpin Buy Rating
PremiumRatingsTransMedics: Expanding Growth Platform, Strong Clinical Catalysts, and Improving Fundamentals Underpin Buy Rating
2M ago
Analyst Reiterates Buy on TransMedics as U.S. Transplant Volumes Accelerate and Aviation Utilization Supports Sustained Growth
Premium
Ratings
Analyst Reiterates Buy on TransMedics as U.S. Transplant Volumes Accelerate and Aviation Utilization Supports Sustained Growth
2M ago
TransMedics Group Ramps Growth With Record Earnings
Premium
Company Announcements
TransMedics Group Ramps Growth With Record Earnings
2M ago
TransMedics price target lowered to $95 from $124 at Canaccord
PremiumThe FlyTransMedics price target lowered to $95 from $124 at Canaccord
3M ago
TransMedics price target lowered to $65 from $80 at Stifel
Premium
The Fly
TransMedics price target lowered to $65 from $80 at Stifel
3M ago
TransMedics reports Q2 adjusted EPS 44c, consensus 48c
Premium
The Fly
TransMedics reports Q2 adjusted EPS 44c, consensus 48c
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―